65,437 trials
Cataracts · Inflammation
Primary: Percentage of Patients With an Anterior Cell Grade of 0 (no Cells) at Day 15 ± 2 Days — 78.9; 77.5 Percentage of patients
Acne Vulgaris
Primary: Change From Baseline in Total and Each Type of Acne Lesions Count at Month 1 — 10.97; 11.43; 4.32; 4.46 Lesions
Bipolar II Disorder · Major Depressive Episode
Primary: The Primary Efficacy Endpoint is the Comparison of Baseline and Week 8 Endpoint in the 17-item HAM-D Total Scores — 23.1; 10.57 Scores on a scale — p=<0.0001
Breakthrough Bleeding
Primary: Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84) — 13; 13.5; 15; 15 days
Atherosclerosis · Percutaneous Coronary Intervention · Acute Coronary Syndrome
Primary: The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST) — 257; 322 participants
Respiratory Syncytial Virus Infection
Primary: Serum Palivizumab Trough Concentrations at Day 1, Day 31, and Day 121 — 0; 59.0; 91.8 µg/mL
Carcinoma, Renal Cell
Primary: Progression-free Survival (PFS) — 8.4; 9.5 Months
Urinary Incontinence (UI)
Primary: Proportion of Women Who Meet Definition of Success — 43; 41 participants — p=0.74
Healthy
Primary: Time to Reach the Maximum Plasma Concentration (Tmax) of Theophylline — 1.25; 1.5 hours — p=0.5663
Bipolar I Disorder
Primary: Proportion of Patients Who Showed no Worsening According to the Clinical Global Impression - Bipolar Version (CGI-BP) Scale (Intent-to-Treat Population) — 26; 14; 16…
Influenza
Primary: Titers for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease — 14.7; 15.6; 14.4; 201.1 Titer
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…
Prostatic Neoplasms · Prostate Cancer
Primary: Percentage of Participants With Prostate Specific Antigen (PSA) Response — 37.9 percentage of participants
Schizophrenia
Primary: Change From Baseline in Weight — 1.7; 2.1 kilograms
Exudative Age Related Macular Degeneration
Primary: Vitreal VEGF Levels. — 735.48; 626.09; 141.11; 235.81 pg/ml